← All stocks

Allogene Therapeutics, Inc.

ALLO Net selling

CIK 0001737287 #2814 in the set updated 18 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$62.96K

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$62.96K

1 of 1 sales

Net

−$62.96K

−$62.96K against sales at will

By person

11 insiders · 1 transaction

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Douglas Earl Martin

SVP, General Counsel

—

$62.96K (1)

−$62.96K

488,267

0.1413%

$1.04M

+21.4%

Chang David D

President and CEO

—

5,150,599

1.49%

$10.92M

+6.5%

Belldegrun Arie

Director

—

2,236,816

0.6474%

$4.74M

+19.8%

Parker Geoffrey M.

CHIEF FINANCIAL OFFICER

—

1,252,795

0.3626%

$2.66M

+6.1%

Roberts Zachary

President and CEO

—

581,166

0.1682%

$1.23M

+12.8%

Kazam Joshua A

Director

—

398,463

0.1153%

$844.74K

+31.5%

Humer Franz B

Director

—

307,507

0.0890%

$651.91K

−2.9%

MOORE TIMOTHY L.

Chief Technical Officer

—

250,713

0.0726%

$531.51K

−5.6%

Beneski Benjamin Machinas

SVP, Chief Technical Officer

—

195,338

0.0565%

$414.12K

+1.6%

Yoshiyama Annie

SVP, Finance

—

124,517

0.0360%

$263.98K

+11.5%

MESSEMER DEBORAH M.

Director

—

107,431

0.0311%

$227.75K

−35.6%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Douglas Earl Martin

21 Aug 2026

SVP, General Counsel

Sell

29,697

$2.12

$62.96K

Show all 1 transactions →

What was left out

Form 4 filings counted 1

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 0

History held since 17 Oct 2018